HOME >> MEDICINE >> NEWS
Use of antibiotic to treat infectious eye disease trachoma may increase risk for reinfection

Use of the antibiotic azithromycin to treat trachoma in Vietnam resulted in an increase in the risk of re-infections, according to a study in the September 27 issue of JAMA.

In 1995, the World Health Organization (WHO) first published data on global blindness and reported that 15 percent of cases were due to trachoma (a contagious bacterial eye disease in which scar tissue forms inside the eyelid and causes infection), making it the second major cause of blindness after cataract. At that time, the WHO estimated that 146 million individuals were in need of treatment for active trachoma to prevent blindness, 10 million were in need of surgery for trachomatous trichiasis (eyelash[es] touching the eye), and 8 million were already blind, according to background information in the article.

In 1996, the WHO designed the SAFE (Surgery for trachomatous trichiasis; Antibiotics for Chlamydia trachomatis (a type of Chlamydia that causes trachoma); Facial cleanliness; and Environmental improvement) strategy with the goal of elimination of blinding trachoma by the year 2020. For the antibiotic arm of the SAFE strategy, the WHO has recommended antibiotic treatment with either topical tetracycline or oral azithromycin for certain categories of patients with active trachoma. Oral azithromycin has become the drug of choice for the SAFE programs because of difficulties concerning administration and adherence with topical tetracycline eye ointment. Despite a number of studies, there has been a lack of sufficient follow-up beyond the final treatment point to determine rates of recurrence of disease and infection and the risk factors that may contribute to each.

Berna Atik, M.D., M.P.H., of Children's Hospital Oakland Research Institute, Oakland, Calif., and colleagues evaluated the effect of targeted oral azithromycin treatment of school age children and their household members in Vietnam on active trachoma and C trachomatis infection rates. Vietnam is
'"/>

Contact: Venita Robinson
510-428-3069
JAMA and Archives Journals
26-Sep-2006


Page: 1 2

Related medicine news :

1. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
2. New contracts support clinical trials on antibiotic-resistant, community-acquired staph infections
3. Plants uptake antibiotics
4. Community-associated staph infections involving antibiotic-resistant bacteria increase
5. Researchers discover how antibiotic inhibits bacterial growth
6. Study finds antibiotic resistance in poultry even when antibiotics were not used
7. Rapid flu testing is associated with decreased antibiotic use in hospitalized adults
8. Rapid flu tests may reduce threat of antibiotic resistance
9. Antibiotic ear drops favored over popular oral antibiotics for ear infections
10. Controlling antibiotics and antibiotic resistance in hospitals
11. Transmission of antibiotic-resistant bacteria linked to previous intensive care unit room occupants

Post Your Comments:
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: